<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-75295</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Comparison of iIodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty</dc:title>
<dc:description xml:lang="en">Introduction and objectives. This study was designed to compare differences in the incidence of contrast-induced nephropathy (CIN) and changes in serum creatinine (SCr) level following iso-osmolar iodixanol or low-osmolar ioversol administration in diabetic patients undergoing coronary angiography, with or without percutaneous coronary intervention (PCI). A number of studies have indicated that iodixanol reduces the risk of CIN in patients with renal impairment, with or without diabetes. Diabetic patients may have some degree of renal dysfunction despite having a normal SCr level. Methods. The study included 250 consecutive diabetic patients undergoing coronary angiography with or without PCI. Those enrolled during the first 7 months of the study received ioversol and those enrolled during the following 11 months received iodixanol. The primary study endpoint was the incidence of CIN. Secondary objectives were to identify independent predictors of CIN and to determine the mean increase in SCr 72 hours after contrast injection. Results. The overall incidence of CIN was 5.6%. The incidence of CIN was significantly lower with iodixanol than with ioversol (2.5% vs. 8.3%, respectively; odds ratio [OR]=0.255; 95% confidence interval [CI], 0.068-0.952; P=.047). A low estimated glomerular filtration rate (60.8±29 mL/min per 1.73 m2 in those with CIN vs. 75.3±25 mL/min per 1.73 m2 in those without; OR=0.975; 95% CI, 0.952-0.997; P=.03) and ioversol use were independent predictors of CIN. Conclusions. In diabetic patients undergoing diagnostic coronary angiography with or without PCI, the iso-osmolar contrast medium iodixanol was associated with a lower incidence of CIN than low-osmolar ioversol (AU)</dc:description>
<dc:creator>García-Tejada, Julio</dc:creator>
<dc:creator>Gómez-Blázquez, Iván</dc:creator>
<dc:creator>Bastante, Teresa</dc:creator>
<dc:creator>Hernández, Felipe</dc:creator>
<dc:creator>Albarrán, Agustín</dc:creator>
<dc:creator>Tascón, Juan</dc:creator>
<dc:creator>Mora, Laura</dc:creator>
<dc:creator>Velázquez, Maite</dc:creator>
<dc:creator>Andreu, Javier</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción y objetivos. Este estudio se diseñó para comparar la incidencia de nefropatía por contraste (NC) y los cambios en la creatinina sérica (CrS) tras el uso del contraste isoosmolar iodixanol o el contraste de baja osmolaridad ioversol en pacientes diabéticos sometidos a coronariografía y/o intervención coronaria percutánea (ICP). Algunos estudios indican que el iodixanol reduce el riesgo de NC en pacientes con disfunción renal, con o sin diabetes. Los pacientes diabéticos pueden tener cierto grado de disfunción renal a pesar de tener niveles normales de CrS. Métodos. Se incluyeron 250 pacientes diabéticos consecutivos a los que se realizó coronariografía y/o ICP. Los pacientes incluidos durante los primeros 7 meses del estudio recibieron ioversol, y los incluidos en los siguientes 11 meses recibieron iodixanol. El objetivo primario del estudio fue la incidencia de NC. Los predictores independientes de NC y el incremento medio de CrS 72 h tras el contraste fueron objetivos secundarios. Resultados. La incidencia total de NC fue del 5,6%. La incidencia de NC fue significativamente menor con iodixanol que con ioversol (el 2,5 frente al 8,3%; odds ratio = 0,255; intervalo de confianza del 95%, 0,068-0,952; p = 0,047). Una menor tasa de filtrado glomerular estimada (60,8 ± 29 frente a 75,3 ± 25 ml/min/1,73 m2; odds ratio = 0,975; intervalo de confianza del 95%, 0,952-0,997; p = 0,03) y el uso de ioversol se demostraron predictores independientes de NC. Conclusiones. En pacientes diabéticos sometidos a coronariografía diagnóstica y/o ICP, el contraste isoos-molar iodixanol mostró menor incidencia de NC que el contraste de baja osmolaridad ioversol (AU)</dc:description>
<dc:source>Rev Esp Cardiol;62(12): 1373-1380, dic. 2009. tab, ilus</dc:source>
<dc:identifier>ibc-75295</dc:identifier>
<dc:title xml:lang="es">Comparación de iodixanol frente a ioversol en la prevención de la nefropatía por contraste tras coronariografía o angioplastia en pacientes diabéticos</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d24519^s28898</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d30178^s28898</dc:subject>
<dc:subject>^d7500^s22073</dc:subject>
<dc:subject>^d3306^s22020</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7182^s22073</dc:subject>
<dc:subject>^d38644</dc:subject>
<dc:subject>^d7849^s22036</dc:subject>
<dc:type>article</dc:type>
<dc:date>200912</dc:date>
</metadata>
</record>
</ibecs-document>
